Drew Moghanaki: Immune checkpoint inhibitors need to be replaced by safer alternatives in the future
Drew Moghanaki, Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, shared a post on X, about a paper by Julie Brahmer et al. published in Science Direct.
“This sobering report is a reminder that while immune checkpoint inhibitors help a substantial subset of patients with advanced cancer, they ultimately need to be replaced by safer alternatives in the future. Our work is far from done.”
Authors: Julie Brahmer, Georgina Long, Omid Hamid, Todd Gruber, Antoni Ribas et al.
More posts featuring Drew Moghanaki.
Dr. Drew Moghanaki, a Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, UCLA. He holds the Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at the same university.
He specializes in treating lung cancer and other thoracic malignancies, focusing on advanced radiation therapy techniques like stereotactic body radiation therapy (SBRT), magnetic resonance-guided radiation therapy (MRgRT), and intensity-modulated radiation therapy (IMRT).
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023